Ferric Citrate in Managing Serum Phosphorus and Iron Deficiency in Anemic Chronic Kidney Disease (CKD) Subjects Not on Dialysis



Status:Completed
Conditions:Iron Deficiency Anemia, Iron Deficiency Anemia, Renal Impairment / Chronic Kidney Disease, Anemia
Therapuetic Areas:Hematology, Nephrology / Urology
Healthy:No
Age Range:18 - Any
Updated:10/22/2017
Start Date:November 2012
End Date:December 2013

Use our guide to learn which trials are right for you!

A Phase 2 Study of KRX-0502 (Ferric Citrate) in Managing Serum Phosphorus and Iron Deficiency in Anemic Subjects With Stage III to V Chronic Kidney Disease Not on Dialysis

The purpose of this study is to determine if KRX-0502 (ferric citrate) is a safe and
effective treatment for the management of serum phosphorus levels and iron deficiency in
anemic chronic kidney disease (CKD) stage 3-5 subjects not on dialysis. Total length of
treatment is approximately 12 weeks.

This is a randomized, double-blind, placebo-controlled, three-period, multi-center clinical
trial. Following a Screening and Qualification Period and a two-week Washout Period (for
those subjects entering the study on a phosphate binder), eligible subjects will be
randomized in a 1:1 ratio to receive either KRX-0502 (ferric citrate) or placebo for up to
approximately 12 weeks. The purpose of this study is to determine if KRX-0502 (ferric
citrate) is a safe and effective treatment for the management of serum phosphorus levels and
iron deficiency in anemic CKD subjects not on dialysis.

Inclusion Criteria:

- Stage III to V Chronic Kidney Disease

- Serum Phosphorus 4.0-6.0 mg/dL prior to Randomization

- Ferritin 300 ng/mL or less

- Transferrin Saturation (TSAT) 30% or less

- Hemoglobin >9.0 and <12.0 g/dL

- Must consume a minimum of 2 meals per day

Exclusion Criteria:

- Parathyroidectomy within 24 weeks of study

- gastrointestinal bleed or inflammatory bowel disease within 12 weeks of study

- Requirement for dialysis or kidney injury within 8 weeks of study

- Absolute requirement for oral iron, intravenous iron, Erythropoiesis-Stimulating
Agent, blood transfusions, and Sensipar during the study

- Absolute requirement for calcium-, magnesium-, or aluminum-containing drugs with meals

- Absolute requirement for vitamin C, niacin, or nicotinamide outside of multivitamins

- History of hemochromatosis

- Allergy to iron products

- History of malignancy in last 5 years
We found this trial at
20
sites
?
mi
from
La Mesa, CA
Click here to add this to my saved trials
?
mi
from
Asheville, NC
Click here to add this to my saved trials
?
mi
from
Bethesda, MD
Click here to add this to my saved trials
?
mi
from
Denver, CO
Click here to add this to my saved trials
?
mi
from
Detroit, MI
Click here to add this to my saved trials
?
mi
from
Edgewater, FL
Click here to add this to my saved trials
?
mi
from
Evergreen Park, IL
Click here to add this to my saved trials
?
mi
from
Great Neck, NY
Click here to add this to my saved trials
?
mi
from
Houston, TX
Click here to add this to my saved trials
?
mi
from
Meridian, ID
Click here to add this to my saved trials
?
mi
from
Miami, FL
Click here to add this to my saved trials
?
mi
from
Mineola, NY
Click here to add this to my saved trials
?
mi
from
Orangeburg, SC
Click here to add this to my saved trials
?
mi
from
Pontiac, MI
Click here to add this to my saved trials
?
mi
from
Reno, NV
Click here to add this to my saved trials
?
mi
from
Sacramento, CA
Click here to add this to my saved trials
?
mi
from
San Antonio, TX
Click here to add this to my saved trials
Springfield, Massachusetts 01199
?
mi
from
Springfield, MA
Click here to add this to my saved trials
?
mi
from
Tempe, AZ
Click here to add this to my saved trials
Wilmington, North Carolina 28401
?
mi
from
Wilmington, NC
Click here to add this to my saved trials